Gracias Jorge A. La había visto y me pareció buena idea. Si te digo la verdad me sigue pareciendo, aunque no tenía ni idea de que estaban tan mal, pero como producto me parece bueno. Y no se pincha, es un spray (lo de la eyaculación)por lo menos lo que están certificando ahora mismo. Gracias de todas formas. Y me alegro que por lo menos te divirtieras un rato. Hay cosas que no se pagan con dinero. :D
Y cada vez se acerca mas a ese 1$ para meterle un tirito de entrada ... :)
Los que la queráis pillar a $1, me da que hoy igual cuela...
S2
A 1,01 tengo la orden puesta. Agazapado y a la espera ...
Según entiendo en la noticia que adjunto, Zalicus ha renovado un año un acuerdo de colaboración que tenia con Novartis, espero que eso sea bueno y suba la acción... ¿que opináis?
Hola gris.
Esa noticia es del viernes y la verdad es que no se notó en la cotización.
No se porque a veces rumores/noticias sientan bien y otras no tanto.
Saludos
Quizas me equivoque, pero al ser una renovacion, es decir, mas de lo mismo, a falta de una noticia mas potente, no creo que afecte significativamente.
A ver si con esto reacciona. De hoy mismo
Zalicus Inc has added a news release to its Investor Relations website.
Title: Zalicus Completes Patient Enrollment in Phase 2b Clinical Trial of Synavive in Rheumatoid Arthritis
Date(s): 30-Apr-2012 7:31 AM
For a complete listing of our news releases, please click here
Top-line Data Planned for Third Quarter 2012
CAMBRIDGE, Mass., Apr 30, 2012 (BUSINESS WIRE) --Zalicus
Inc. (NASDAQ: ZLCS), a biopharmaceutical company that discovers and
develops novel treatments for patients suffering from pain and
immuno-inflammatory diseases, today announced it has completed
enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b
clinical trial designed to evaluate the safety and efficacy of
Synavive(R), a low-dose glucocorticoid with the potential for amplified
immuno-inflammatory benefits, in patients with rheumatoid arthritis
(RA). Top-line results of the clinical trial are expected to be
available in the third quarter of 2012.
"The completion of patient enrollment in SYNERGY is an important
milestone for Zalicus. We are grateful to the investigators and patients
for participating in this study and look forward to reporting top-line
results in the third quarter of 2012," commented Mark H.N. Corrigan, MD,
President and CEO of Zalicus. "Synavive has already demonstrated early
and encouraging signs of clinical efficacy in RA in a previously
completed Phase 2a study with statistically significant improvements in
ACR20 and DAS28 scores compared to placebo."
Study Design and Objectives
The Phase 2b clinical trial titled SYNERGY (SYNavivE for Reducing signs
and sYmptoms of rheumatoid arthritis trial), is a 12-week, five-arm,
global, double-blind, placebo-controlled study designed to evaluate the
safety and efficacy of Synavive as a treatment for the signs and
symptoms of RA in subjects with moderate to severe disease. The trial is
being conducted in up to 60 centers throughout the United States, Europe
and Latin America. The primary objective of the trial is to evaluate
Synavive efficacy compared to placebo, while key additional secondary
objectives include evaluating the efficacy of Synavive compared to its
individual components (2.7mg of Prednisolone and 360mg of
Dipyramidamole) as well as how Synavive performs in comparison to 5mg of
Prednisone. Subjects who complete the core SYNERGY trial are eligible to
participate in a one-year extension study designed to investigate the
long-term safety and durability of response for Synavive. To learn more
about the SYNERGY trial please visit www.clinicaltrials.gov.
About Synavive
Synavive is a novel product candidate designed to enhance the
anti-inflammatory benefits of glucocorticoids, without associated
dose-dependent side effects. Synavive contains the cardiovascular agent
dipyridamole and a very low dose of the glucocorticoid prednisolone and
has been designed for once-daily use in a unique fixed-dose, aligned
release, oral formulation. Synavive is thought to act through a novel
multi-target mechanism of action in which dipyridamole synergistically
and selectively amplifies prednisolone's anti-inflammatory and
immunomodulatory activities by inhibiting key cell mediators of
inflammation. In prior proof-of-concept clinical trials, Synavive
demonstrated a powerful anti-inflammatory effect in patients with
rheumatoid arthritis (RA) and osteoarthritis (OA) and was generally
well-tolerated. Synavive is currently in Phase 2 clinical development
for the treatment of rheumatoid arthritis (RA). Beyond RA, Synavive has
potential in other steroid-responsive diseases such as polymyalgia
rheumatica (PMR), lupus (SLE), ulcerative colitis, and Crohn's as well
as a potential replacement of NSAIDs and COXIB's in osteoarthritis.
About Zalicus
Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain
and immuno-inflammatory diseases. Zalicus has a portfolio of proprietary
clinical-stage product candidates targeting pain and immuno-inflammatory
diseases and have entered into multiple revenue-generating
collaborations with large pharmaceutical companies relating to other
products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening
capabilities to discover innovative therapeutics for itself and its
collaborators in the areas of pain, inflammation, oncology and
infectious disease.
To learn more about Zalicus, please visit www.zalicus.com.
Forward-Looking Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
concerning Zalicus, its product candidate Synavive and its potential and
its other business plans. These forward-looking statements about future
expectations, plans, objectives and prospects of Zalicus may be
identified by words like "believe," "expect," "may," "will," "should,"
"seek," "plan" or "could" and similar expressions and involve
significant risks, uncertainties and assumptions, including risks
related to the clinical development of Synavive, the unproven nature of
the Zalicus cHTS drug discovery technology, the Company's ability to
obtain additional financing or funding for its research and development
and those other risks that can be found in the "Risk Factors" section of
Zalicus' annual report on Form 10-K on file with the Securities and
Exchange Commission and the other reports that Zalicus periodically
files with the Securities and Exchange Commission. Actual results may
differ materially from those Zalicus contemplated by these
forward-looking statements. These forward-looking statements reflect
management's current views and Zalicus does not undertake to update any
of these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release except
as required by law.
(c) 2012 Zalicus Inc. All rights reserved.
SOURCE: Zalicus Inc.
Zalicus Inc.
Justin Renz, CFO, 617-301-7575
[email protected]
or
Gina
Nugent, 617-460-3579
[email protected]
If you are unable to click on the link above, please copy and paste the URL below into a web browser
http://phx.corporate-ir.net/phoenix.zhtml?c=148036&p=irol-news&nyo=0
Thomson Reuters Inc. 22 Thomson Place Boston, MA 02210
Click Here to unsubscribe from this JoinMail list.
